Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ciclosporin ophthalmic - Laboratoires Thea

Next Previous
Drug Profile

Ciclosporin ophthalmic - Laboratoires Thea

Alternative Names: T-1580; T1580 ophthalmic

Latest Information Update: 15 Feb 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Laboratoires Thea
  • Class Anti-inflammatories; Antineoplastics; Antipsoriatics; Antirheumatics; Ciclosporins; Eye disorder therapies; Heart failure therapies; Neuroprotectants
  • Mechanism of Action Calcineurin inhibitors; Immunosuppressants; Mitochondrial permeability transition pore inhibitors; P-glycoprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Dry eyes

Most Recent Events

  • 15 Feb 2022 Phase III development in Dry eyes is ongoing in Belgium and Italy (EudraCT2015-005405-36)
  • 15 Feb 2022 No development reported - Phase-III for Dry eyes (In the elderly, In adults) in United Kingdom, Spain, Poland, Czech Republic, Croatia, Bulgaria, Greece, Lithuania, Austria, Latvia, Hungary (Ophthalmic)
  • 17 May 2016 Phase-III clinical trials in Dry eyes (In adults, In the elderly) in Greece, Lithuania, Austria, Latvia, Hungary (Ophthalmic) (EudraCT2015-005405-36)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top